A Phase 1/2 interventional study of Acalabrutinib and Pembrolizumab in Follicular Lymphoma (FL), CLL and Small Lymphocytic Lymphoma (SLL), sponsored by Acerta Pharma BV. Completed at 19 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Lymphoma, Follicular by AstraZeneca — 4 open to participants now, 6 under way, 1 of them phase 3. Lymphoma, Follicular · AstraZeneca.
Among the 17 studies in Lymphoma, Follicular by AstraZeneca, this one is the 7th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2015, is one of 4 in phase 1/2, and was the 7th registered.
1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
Browse Lymphoma, Follicular studies →4 of the 17 studies in Lymphoma, Follicular by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States
Ages 18–85 · Healthy volunteers
AstraZeneca · Sites in United States, Australia, Brazil and 13 more countries
Ages 18+
AstraZeneca · Sites in United States, Australia, Canada and 7 more countries
Ages 18+
AstraZeneca · Sites in United States, Australia, Belgium and 22 more countries
Ages 18–130
By country, each count listing its studies:
Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 7 · Phase 3 2
First in 2003; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 161 is above the median of 48 across 1,503 interventional studies indexed under Lymphoma, Follicular.
Median enrollment 130 across the 16 interventional studies, 1,182 across the 1 observational. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Acerta Pharma BV, one of the names counted as AstraZeneca. Under that name alone:
Acerta Pharma BV is the lead sponsor of 41 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 3 (25%) have results posted.
1 of the studies in Lymphoma, Follicular by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07546760AstraZenecaA Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234 | 2027-02-04 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Lymphoma, Follicular by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.
This is a Phase 1b/2, open-label, nonrandomized study that will be conducted in 2 stages. In the first stage, Part 1 of the study will determine the safety and preliminary efficacy of acalabrutinib and pembrolizumab in a limited group of B-cell malignancies. In the second stage, Part 2 allows for possible expansion cohorts into a wider range of B-cell malignancies, and Part 3 will evaluate the combination in subjects with myelofibrosis (MF).
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A nonrandomized study that will be conducted in 2 stages. In the first stage, (Safety), subjects will receive Acalabrutinib Dose A orally administered (PO) twice daily (BID) in combination with Pembrolizumab Dose B administered every 3 weeks (Q3W). The second stage was an expansion of Cohorts with the same dose regimen as the first stage. An additional expansion in subjects with Myelofibrosis was planned but not conducted.
Drug: Acalabrutinib · Drug: Pembrolizumab
Orally Administered (PO)
Also known as: ACP-196
Intravenous Administered (IV)
Also known as: KEYTRUDA
Number of Participants With Treatment Emergent Adverse Events (AEs)
Treatment-emergent AEs were defined as those events that occurred on or after the first dose of study drug, through the treatment phase, and within 30 days following the last dose of study drug.
Time frame: 104 weeks
Number of Participants With Grade 3-4 Adverse Events
Severity of AEs was graded using the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03
Time frame: 104 weeks
Number of Participants With Grade 5 Adverse Events
Number of participants with CTCAE Grade 5 (fatal) adverse events
Time frame: 104 weeks
Number of Participants With Any Study-Drug Related AE
Study drug-related AEs were those assessed by investigator as related to study treatment.
Time frame: 104 weeks
Number of Participants With Grade 3-4 Study-Drug Related AE
The severity of the AEs was assessed by NCI CTCAE Version 4.03 or higher. Drug-related AEs were those assessed by investigator as related to study treatment.
Time frame: 104 weeks
Number of Participants With Grade 5 Study-Drug Related AE
Grade 5 (fatal) AEs assessed by investigator as related to study treatment.
Time frame: 104 weeks
Number of Participants With Any SAE
Serious AEs were those that resulted in death, were life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product, or were considered a significant medical event by the investigator based on medical judgment.
Time frame: 104 weeks
Number of Participants With Grade 3-4 Any SAE
Serious AEs were those that resulted in death, were life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product, or were considered a significant medical event by the investigator based on medical judgment. The severity of the AEs was assessed by NCI CTCAE Version 4.03 or higher.
Time frame: 104 weeks
Number of Participants With Grade 5 Any SAE
Grade 5 events were fatal events. Serious AEs were those that resulted in death, were life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product, or were considered a significant medical event by the investigator based on medical judgment.
Time frame: 104 weeks
Number of Participants With Any Study Drug-Related SAE
Serious AEs were those that resulted in death, were life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product, or were considered a significant medical event by the investigator based on medical judgment. Drug-related AEs were those assessed by investigator as related to study treatment.
Time frame: 104 weeks
Number of Participants With Any Grade 3-4 Study Drug-Related SAE
Serious AEs were those that resulted in death, were life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product, or were considered a significant medical event by the investigator based on medical judgment. The severity of the AEs was assessed by NCI CTCAE Version 4.03 or higher. Drug-related AEs were those assessed by investigator as related to study treatment.
Time frame: 104 weeks
Number of Participants With Any Grade 5 Study Drug-Related SAE
Grade 5 AEs were fatal events. Serious AEs were those that resulted in death, were life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product, or were considered a significant medical event by the investigator based on medical judgment. Drug-related AEs were those assessed by investigator as related to study treatment.
Time frame: 104 weeks
Number of Participants With AE Leading to Study Drug Discontinuation, Modification or Delay
AEs that discontinuation of study treatment, or a reduction in dosage, or a delay (temporary withholding) in treatment.
Time frame: 104 weeks
Number of Participants With AE Leading to Study Drug Discontinuation
An adverse event that resulted in the permanent discontinuation of study treatment in the study.
Time frame: 104 weeks
Number of Participants With AE Leading to Study Drug Delay
An adverse event that caused a temporary withholding of study treatment.
Time frame: 104 weeks
Number of Participants With AE Leading to Study Drug Modification
An adverse event that resulted in a reduction in the dosage of study treatment for that participant.
Time frame: 104 weeks
Overall Response Rate
The percentage of subjects who achieve a partial response or complete response
Time frame: 104 weeks
Duration of Response
The interval from the first documentation of response to the earlier of the first documentation of definitive disease progression or death from any cause
Time frame: 104 weeks
Progression-free Survival
The interval from the first dose date of acalabrutinib or pembrolizumab to the earlier of the first documentation of objective disease progression or death from any cause
Time frame: 104 weeks
Overall Survival
The time from the first dose date of acalabrutinib or pembrolizumab until date of death due to any cause
Time frame: 104 weeks
Time to Next Treatment
The time from the first dose date of acalabrutinib or pembrolizumab to the start of the next treatment other than the study treatment
Time frame: 104 weeks
| Milestone | Acalabrutinib + Pembrolizumab |
|---|---|
| Started | 161 |
| Completed | 0 |
| Not completed | 161 |
| Withdrew: Death | 67 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Adverse event | 1 |
| Withdrew: Physician decision | 1 |
| Withdrew: Subject started another cancer therapy | 10 |
| Withdrew: Study terminated by sponsor | 45 |
| Withdrew: Decision by subject not related to ae/sae | 2 |
| Withdrew: Decision by pi not related to ae/sae | 1 |
| Withdrew: Disease progression | 11 |
| Withdrew: Withdrawal by subject | 20 |
Treatment-emergent AEs were defined as those events that occurred on or after the first dose of study drug, through the treatment phase, and within 30 days following the last dose of study drug.
| Number of participants | Acalabrutinib + Pembrolizumab |
|---|---|
| Number of Participants With Treatment Emergent Adverse Events (AEs) | 160 |
Severity of AEs was graded using the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03
| Number of participants | Acalabrutinib + Pembrolizumab |
|---|---|
| Number of Participants With Grade 3-4 Adverse Events | 105 |
Number of participants with CTCAE Grade 5 (fatal) adverse events
| Number of participants | Acalabrutinib + Pembrolizumab |
|---|---|
| Number of Participants With Grade 5 Adverse Events | 9 |
Study drug-related AEs were those assessed by investigator as related to study treatment.
| Number of participants | Acalabrutinib + Pembrolizumab |
|---|---|
| Number of Participants With Any Study-Drug Related AE | 142 |
The severity of the AEs was assessed by NCI CTCAE Version 4.03 or higher. Drug-related AEs were those assessed by investigator as related to study treatment.
| Number of participants | Acalabrutinib + Pembrolizumab |
|---|---|
| Number of Participants With Grade 3-4 Study-Drug Related AE | 66 |
Grade 5 (fatal) AEs assessed by investigator as related to study treatment.
| Number of participants | Acalabrutinib + Pembrolizumab |
|---|---|
| Number of Participants With Grade 5 Study-Drug Related AE | 3 |
Serious AEs were those that resulted in death, were life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product, or were considered a significant medical event by the investigator based on medical judgment.
| Number of participants | Acalabrutinib + Pembrolizumab |
|---|---|
| Number of Participants With Any SAE | 75 |
Serious AEs were those that resulted in death, were life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product, or were considered a significant medical event by the investigator based on medical judgment. The severity of the AEs was assessed by NCI CTCAE Version 4.03 or higher.
| Number of participants | Acalabrutinib + Pembrolizumab |
|---|---|
| Number of Participants With Grade 3-4 Any SAE | 64 |
Grade 5 events were fatal events. Serious AEs were those that resulted in death, were life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product, or were considered a significant medical event by the investigator based on medical judgment.
| Number of participants | Acalabrutinib + Pembrolizumab |
|---|---|
| Number of Participants With Grade 5 Any SAE | 9 |
Serious AEs were those that resulted in death, were life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product, or were considered a significant medical event by the investigator based on medical judgment. Drug-related AEs were those assessed by investigator as related to study treatment.
| Number of participants | Acalabrutinib + Pembrolizumab |
|---|---|
| Number of Participants With Any Study Drug-Related SAE | 34 |
Serious AEs were those that resulted in death, were life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product, or were considered a significant medical event by the investigator based on medical judgment. The severity of the AEs was assessed by NCI CTCAE Version 4.03 or higher. Drug-related AEs were those assessed by investigator as related to study treatment.
| Number of participants | Acalabrutinib + Pembrolizumab |
|---|---|
| Number of Participants With Any Grade 3-4 Study Drug-Related SAE | 30 |
Grade 5 AEs were fatal events. Serious AEs were those that resulted in death, were life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product, or were considered a significant medical event by the investigator based on medical judgment. Drug-related AEs were those assessed by investigator as related to study treatment.
| Number of participants | Acalabrutinib + Pembrolizumab |
|---|---|
| Number of Participants With Any Grade 5 Study Drug-Related SAE | 3 |
AEs that discontinuation of study treatment, or a reduction in dosage, or a delay (temporary withholding) in treatment.
| Number of participants | Acalabrutinib + Pembrolizumab |
|---|---|
| Number of Participants With AE Leading to Study Drug Discontinuation, Modification or Delay | 83 |
An adverse event that resulted in the permanent discontinuation of study treatment in the study.
| Number of participants | Acalabrutinib + Pembrolizumab |
|---|---|
| Number of Participants With AE Leading to Study Drug Discontinuation | 45 |
An adverse event that caused a temporary withholding of study treatment.
| Number of participants | Acalabrutinib + Pembrolizumab |
|---|---|
| Number of Participants With AE Leading to Study Drug Delay | 71 |
An adverse event that resulted in a reduction in the dosage of study treatment for that participant.
| Number of participants | Acalabrutinib + Pembrolizumab |
|---|---|
| Number of Participants With AE Leading to Study Drug Modification | 9 |
The percentage of subjects who achieve a partial response or complete response
| percent | Acalabrutinib + Pembrolizumab |
|---|---|
| Overall Response Rate | 38.5 (31.0 to 46.5) |
The interval from the first documentation of response to the earlier of the first documentation of definitive disease progression or death from any cause
| Months | Acalabrutinib + Pembrolizumab |
|---|---|
| Duration of Response | 28.5 (9.0 to 36.4) |
The interval from the first dose date of acalabrutinib or pembrolizumab to the earlier of the first documentation of objective disease progression or death from any cause
| Months | Acalabrutinib + Pembrolizumab |
|---|---|
| Progression-free Survival | 4.7 (3.3 to 6.9) |
The time from the first dose date of acalabrutinib or pembrolizumab until date of death due to any cause
| Months | Acalabrutinib + Pembrolizumab |
|---|---|
| Overall Survival | 50.4 (26.2 to NA) |
The time from the first dose date of acalabrutinib or pembrolizumab to the start of the next treatment other than the study treatment
| Months | Acalabrutinib + Pembrolizumab |
|---|---|
| Time to Next Treatment | 21.1 (10.5 to 34.7) |
Collected over For each subject, adverse event data were collected from first dose of study drug until 30 days after the last dose, until the end of the study (data cutoff date of 14 July 2020).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Acalabrutinib + Pembrolizumab | 69/161 (42.9%) | 75/161 (46.6%) | 157/161 (97.5%) |
| Event | Acalabrutinib + Pembrolizumab |
|---|---|
| PneumoniaInfections and infestations | 9/161 |
| SepsisInfections and infestations | 5/161 |
| Aspartate aminotransferase increasedInvestigations | 4/161 |
| Acute kidney injuryRenal and urinary disorders | 4/161 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 4/161 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 3/161 |
| Alanine aminotransferase increasedInvestigations | 3/161 |
| DehydrationMetabolism and nutrition disorders | 3/161 |
| HyponatraemiaMetabolism and nutrition disorders | 3/161 |
| Mental status changesPsychiatric disorders | 3/161 |
| Event | Acalabrutinib + Pembrolizumab |
|---|---|
| DiarrhoeaGastrointestinal disorders | 73/161 |
| FatigueGeneral disorders | 57/161 |
| HeadacheNervous system disorders | 57/161 |
| CoughRespiratory, thoracic and mediastinal disorders | 44/161 |
| NauseaGastrointestinal disorders | 43/161 |
| Decreased appetiteMetabolism and nutrition disorders | 42/161 |
| AnaemiaBlood and lymphatic system disorders | 35/161 |
| VomitingGastrointestinal disorders | 33/161 |
| DizzinessNervous system disorders | 32/161 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 29/161 |
All participants in this study received both study drugs and were therefore analyzed together as a single treatment arm. Participants receiving the different regimens were not analyzed separately by regimen, as the study was designed to assess the safety of the combination study treatment.
| Age, Continuous(Years) | Acalabrutinib + Pembrolizumab |
|---|---|
| Mean | 62.4 ± 14.6 |
| Sex: Female, Male(Participants) | Acalabrutinib + Pembrolizumab |
|---|---|
| Female | 63 |
| Male | 98 |
| Race/Ethnicity, Customized(Participants) | Acalabrutinib + Pembrolizumab |
|---|---|
| Hispanic or Latino | 11 |
| Not Hispanic or Latino | 148 |
| Not Reported | 2 |
| Race/Ethnicity, Customized(Participants) | Acalabrutinib + Pembrolizumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 4 |
| Black or African American | 5 |
| Native Hawaiian or Other Pacific Islander | 2 |
| White | 141 |
| Not Reported | 9 |
| Region of Enrollment(Participants) | Acalabrutinib + Pembrolizumab |
|---|---|
| USA | 161 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Feb 2015 to primary completion in Jul 2020, 64 months.
Results were first posted in May 2022, 1 year 9 months after primary completion.
Of 43 industry-sponsored phase 1/2 interventional studies under Lymphoma, Follicular, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 103. This study's 64 months is close to that.
Counting every sponsor, half of 88 studies reached it within 73 months; a quarter within 50 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acalabrutinib